XPhyto signs transformative acquisition agreement with 3a-diagnostics
Enter hi-tech biosensor market and expand its diagnostic product portfolio
XPhyto Therapeutics Corp. announced that it has signed a definitive agreement for the acquisition of 3a-diagnostics GmbH, Frickenhausen, Germany. Pursuant to the definitive agreement, XPhyto will acquire all of the outstanding shares of 3a for EUR 400,000, to be paid immediately, and EUR 3.5 million, to be paid on closing, planned for on or around October 31, 2021.
Symbolic image
pixabay.com
Hugh Rogers, CEO of XPhyto said, “We have collaborated closely with the 3a-diagnostics team on several diagnostics products and have found them to be a highly innovative and focused partner. The successful development and recent launch of the 25-minute PCR test COVID-ID Lab is a great example of our fruitful collaboration. We strongly believe that this acquisition will result in powerful synergies and further feed XPhyto’s diagnostic pipeline, supporting our long-term commercial growth plans.”
In April 2020, XPhyto and 3a signed a definitive development, technology purchase and license agreement for the development and commercialization of real-time, low-cost and easy-to-use biosensor screening tests and related development platform for the rapid detection of infectious diseases. This agreement was amended in July 2020 to include 3a’s proprietary enhanced RNA screening system, related intellectual property (IP) and exclusive commercialization rights for its rapid COVID-19 tests. In March 2021, XPhyto and 3a received European commercial approval for their 25-minute PCR test.
The planned acquisition of 3a is expected to result in significant synergies in research and development and manufacturing; significantly improved margins for commercial products, such as the 25-minute COVID-ID Lab test; as well as expedite commercialization of products in 3a’s near-market development pipeline. 3a’s intellectual property, including patents, know-how, expertise and contracts with third parties will be transferred to XPhyto at the time of closing the acquisition. XPhyto plans to maintain, support and further develop 3a’s operations in Southern-Germany.
“This agreement underscores the value of our experienced team and proven track record. We look forward to the completion of the transaction and joining XPhyto and believe that together we will develop and commercialize many great products in both the diagnostic and biosensor markets” noted Dr. Heinrich Jehle, Managing Director of 3a-diagnostics GmbH.
Wolfgang Probst, Director Germany of XPhyto added: “With our activities currently focused on Europe and the Middle East, 3a-diagnostics, with its facilities near Stuttgart, is a valuable addition to our Germany-based operations. 3a-diagnostics has an attractive pipeline, experienced team and is well respected for their work in the development and commercialization of innovative diagnostic products. They perfectly complement our existing capabilities and contribute to XPhyto’s successful corporate development.”
Other news from the department business & finance
These products might interest you
Octet R2 / Octet R4 / Octet R8 by Sartorius
Full power on 2, 4 or 8 channels: Label-free and GxP-compliant analysis of molecular interactions
Innovative label-free real-time protein quantification, binding kinetics and rapid screenings
Octet SF3 by Sartorius
Surface Plasmon Resonance (SPR) using Single Dynamic Injections for Kinetics and Affinities
Curvature is Key - Adding a ‘Third Dimension’ to the Binding Curve
Octet RH16 and RH96 by Sartorius
Efficient protein analysis for process optimisation and manufacturing control in high-throughput
Label-free protein quantification and characterization of protein-protein interactions
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
